**Update 1/5/2021**

Evidence Synthesis

No updates

Medication Collaboratory (Alexandra)

* Review meeting today.
* Aim to award planning funds to develop more complete proposals. Separate Coordinating Center/Methods activity from Long Term Outcomes project. Will need to coordinate long-term outcomes project with NIH and FDA.
* Remdesivir analysis will be presented to Methods WG this week.
* Question from Congress about Fluvoxamine.

Non COVID Impacts: (Stephanie)

* Solicitation for a Data Core/Coordinating Center + Concept papers for individual projects to be released next Monday; due mid-February.

F/U research on COVID Vaccine (Miho/Maciej)

* QUERI teams actively working at three sites. Proposals for longer research due Jan 21

Modeling and COVID (Miho)

* Discussion with Kameron Mathews and NCP decided to defer briefing with EIC, explicit use of models. May still be value once we hit 1c recommendation group where supply << priority group.
* Revised MS ready for submission to JAMA Network
* We’ve asked teams to examine a few questions about change in risk factors over course of epidemic – e.g. is race/ethnicity still a risk factor for infection as pandemic has progressed to different regions?

Phase 4 Vaccine Studies

* Meeting planned with Vicky and Maciej to discuss path for developing CSP-type study that would be aligned with other national efforts (FDA, NIH, CDC)
* Dawn Provenzale developing concept proposal for consideration at Vickie’s request. We have priorities from Fran Cunningham in PBM. Maciej assisting.
* NOTE: Resources not yet identified for this (was it in OWS request?)

CLCs: Question from Michael Gelman about use of rapid antigen testing for CLC staff screening. Propose we develop a research project to compare screening approaches (e.g. Ag vs. PCR)

Disparities: No updates

Data: No update

Registry: No update